vs
Apellis Pharmaceuticals, Inc.（APLS）与Tempus AI, Inc.（TEM）财务数据对比。点击上方公司名可切换其他公司
Tempus AI, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$367.2M vs $199.9M），Tempus AI, Inc.净利率更高（-14.8% vs -29.5%，领先14.7%），Tempus AI, Inc.同比增速更快（83.0% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-41.5M），过去两年Tempus AI, Inc.的营收复合增速更高（58.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Tempus AI是2015年由埃里克·莱夫科夫斯基在美国伊利诺伊州芝加哥创立的医疗科技企业，创立契机源于其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
APLS vs TEM — 直观对比
营收规模更大
TEM
是对方的1.8倍
$199.9M
营收增速更快
TEM
高出88.9%
-5.9%
净利率更高
TEM
高出14.7%
-29.5%
自由现金流更多
APLS
多$27.3M
$-41.5M
两年增速更快
TEM
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $367.2M |
| 净利润 | $-59.0M | $-54.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -16.7% |
| 净利率 | -29.5% | -14.8% |
| 营收同比 | -5.9% | 83.0% |
| 净利润同比 | -62.2% | -316.2% |
| 每股收益（稀释后） | $-0.40 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTEM
| Q4 25 | $199.9M | $367.2M | ||
| Q3 25 | $458.6M | $334.2M | ||
| Q2 25 | $178.5M | $314.6M | ||
| Q1 25 | $166.8M | $255.7M | ||
| Q4 24 | $212.5M | $200.7M | ||
| Q3 24 | $196.8M | $180.9M | ||
| Q2 24 | $199.7M | $166.0M | ||
| Q1 24 | $172.3M | $145.8M |
净利润APLSTEM
| Q4 25 | $-59.0M | $-54.2M | ||
| Q3 25 | $215.7M | $-80.0M | ||
| Q2 25 | $-42.2M | $-42.8M | ||
| Q1 25 | $-92.2M | $-68.0M | ||
| Q4 24 | $-36.4M | $-13.0M | ||
| Q3 24 | $-57.4M | $-75.8M | ||
| Q2 24 | $-37.7M | $-552.2M | ||
| Q1 24 | $-66.4M | $-64.7M |
营业利润率APLSTEM
| Q4 25 | -25.6% | -16.7% | ||
| Q3 25 | 48.7% | -18.3% | ||
| Q2 25 | -18.6% | -19.6% | ||
| Q1 25 | -50.0% | -26.9% | ||
| Q4 24 | -12.3% | -25.3% | ||
| Q3 24 | -24.0% | -29.6% | ||
| Q2 24 | -14.7% | -321.4% | ||
| Q1 24 | -36.0% | -36.5% |
净利率APLSTEM
| Q4 25 | -29.5% | -14.8% | ||
| Q3 25 | 47.0% | -23.9% | ||
| Q2 25 | -23.6% | -13.6% | ||
| Q1 25 | -55.3% | -26.6% | ||
| Q4 24 | -17.1% | -6.5% | ||
| Q3 24 | -29.2% | -41.9% | ||
| Q2 24 | -18.9% | -332.7% | ||
| Q1 24 | -38.5% | -44.4% |
每股收益（稀释后）APLSTEM
| Q4 25 | $-0.40 | $-0.30 | ||
| Q3 25 | $1.67 | $-0.46 | ||
| Q2 25 | $-0.33 | $-0.25 | ||
| Q1 25 | $-0.74 | $-0.40 | ||
| Q4 24 | $-0.30 | $2.56 | ||
| Q3 24 | $-0.46 | $-0.46 | ||
| Q2 24 | $-0.30 | $-6.86 | ||
| Q1 24 | $-0.54 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $604.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $491.3M |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTEM
| Q4 25 | $466.2M | $604.8M | ||
| Q3 25 | $479.2M | $655.9M | ||
| Q2 25 | $370.0M | $186.3M | ||
| Q1 25 | $358.4M | $151.6M | ||
| Q4 24 | $411.3M | $341.0M | ||
| Q3 24 | $396.9M | $388.0M | ||
| Q2 24 | $360.1M | $478.8M | ||
| Q1 24 | $325.9M | $79.9M |
总债务APLSTEM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTEM
| Q4 25 | $370.1M | $491.3M | ||
| Q3 25 | $401.2M | $507.8M | ||
| Q2 25 | $156.3M | $309.6M | ||
| Q1 25 | $164.2M | $326.2M | ||
| Q4 24 | $228.5M | $56.3M | ||
| Q3 24 | $237.1M | $53.7M | ||
| Q2 24 | $264.3M | $98.3M | ||
| Q1 24 | $266.7M | $-1.5B |
总资产APLSTEM
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $2.3B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.5B | ||
| Q4 24 | $885.1M | $926.1M | ||
| Q3 24 | $901.9M | $971.7M | ||
| Q2 24 | $904.5M | $864.6M | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSTEM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-36.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-41.5M |
| 自由现金流率自由现金流/营收 | -7.1% | -11.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-239.1M |
8季度趋势，按日历期对齐
经营现金流APLSTEM
| Q4 25 | $-14.2M | $-36.8M | ||
| Q3 25 | $108.5M | $-119.8M | ||
| Q2 25 | $4.4M | $44.2M | ||
| Q1 25 | $-53.4M | $-105.6M | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | $48.7M | ||
| Q2 24 | $-8.3M | $-97.1M | ||
| Q1 24 | $-133.0M | $-101.4M |
自由现金流APLSTEM
| Q4 25 | $-14.3M | $-41.5M | ||
| Q3 25 | $108.3M | $-126.5M | ||
| Q2 25 | $4.4M | $36.6M | ||
| Q1 25 | $-53.4M | $-107.7M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $48.6M | ||
| Q2 24 | $-8.4M | $-105.1M | ||
| Q1 24 | $-133.3M | $-107.5M |
自由现金流率APLSTEM
| Q4 25 | -7.1% | -11.3% | ||
| Q3 25 | 23.6% | -37.9% | ||
| Q2 25 | 2.5% | 11.6% | ||
| Q1 25 | -32.0% | -42.1% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 26.9% | ||
| Q2 24 | -4.2% | -63.3% | ||
| Q1 24 | -77.3% | -73.7% |
资本支出强度APLSTEM
| Q4 25 | 0.1% | 1.3% | ||
| Q3 25 | 0.0% | 2.0% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 4.8% | ||
| Q1 24 | 0.2% | 4.2% |
现金转化率APLSTEM
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TEM
暂无分部数据
